Avid Bioservices Inc (CDMO)

[entdoc]

disco, see post 47733. The conference you mention appears to be all about the same (or similar) efforts mentioned in 47733, targeting cell envelope GLYCOprotein docking sites to prevent virus entry rather than LIPOprotein docking sites used by Bavi to interfere with viral exit strategy and enhance immune response. My take on it is that Haynes is orchestrating a dual strategy, using both. Should be an interesting conference, as you said, but not directly related to Bavi or PPHM.